CR20230223A - Composiciones farmacéuticas de un inhibidor de cinasa - Google Patents

Composiciones farmacéuticas de un inhibidor de cinasa

Info

Publication number
CR20230223A
CR20230223A CR20230223A CR20230223A CR20230223A CR 20230223 A CR20230223 A CR 20230223A CR 20230223 A CR20230223 A CR 20230223A CR 20230223 A CR20230223 A CR 20230223A CR 20230223 A CR20230223 A CR 20230223A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
kinase inhibitor
relates
modulating
disorder
Prior art date
Application number
CR20230223A
Other languages
English (en)
Inventor
Iswadi Liejanto
Tzu-Yuan Chen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20230223A publication Critical patent/CR20230223A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención hace referencia a con composiciones farmacéuticas del inhibidor c-Met, Compuesto 1. La invención también hace referencia a métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos parcialmente por la modulación de la actividad in vivo de una proteína cinasa con la composición farmacéutica y a procesos para producir las composiciones farmacéuticas.
CR20230223A 2020-11-05 2021-11-04 Composiciones farmacéuticas de un inhibidor de cinasa CR20230223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05
PCT/US2021/057996 WO2022098828A1 (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CR20230223A true CR20230223A (es) 2023-07-07

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230223A CR20230223A (es) 2020-11-05 2021-11-04 Composiciones farmacéuticas de un inhibidor de cinasa

Country Status (15)

Country Link
US (1) US20230398108A1 (es)
EP (1) EP4240333A1 (es)
JP (1) JP2023548855A (es)
KR (1) KR20230104186A (es)
CN (1) CN116406261A (es)
AU (1) AU2021374669A1 (es)
CA (1) CA3196001A1 (es)
CL (1) CL2023001268A1 (es)
CO (1) CO2023005942A2 (es)
CR (1) CR20230223A (es)
IL (1) IL302485A (es)
MX (1) MX2023005273A (es)
PE (1) PE20240223A1 (es)
TW (1) TW202227061A (es)
WO (1) WO2022098828A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200115582A (ko) * 2018-01-26 2020-10-07 엑셀리시스, 인코포레이티드 키나제-의존성 장애의 치료용 화합물
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724342B2 (en) * 2010-07-16 2017-08-08 Exelixis, Inc. C-met modulator pharmaceutical compositions
WO2014165786A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
KR20200115582A (ko) 2018-01-26 2020-10-07 엑셀리시스, 인코포레이티드 키나제-의존성 장애의 치료용 화합물
CR20210375A (es) 2018-12-13 2021-08-18 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
CA3123985A1 (en) * 2018-12-24 2020-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Also Published As

Publication number Publication date
TW202227061A (zh) 2022-07-16
WO2022098828A1 (en) 2022-05-12
US20230398108A1 (en) 2023-12-14
MX2023005273A (es) 2023-05-23
CO2023005942A2 (es) 2023-05-19
CN116406261A (zh) 2023-07-07
KR20230104186A (ko) 2023-07-07
CL2023001268A1 (es) 2023-12-11
IL302485A (en) 2023-06-01
AU2021374669A1 (en) 2023-06-15
JP2023548855A (ja) 2023-11-21
AU2021374669A9 (en) 2024-04-18
EP4240333A1 (en) 2023-09-13
CA3196001A1 (en) 2022-05-12
PE20240223A1 (es) 2024-02-16

Similar Documents

Publication Publication Date Title
CR20230223A (es) Composiciones farmacéuticas de un inhibidor de cinasa
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2021006951A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa.
EA200001258A1 (ru) Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
HK1116161A1 (en) Substituted amide derivatives as protein kinase inhibitors
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
SG162747A1 (en) Erythropoietin receptor peptide formulations and uses
MX2021012706A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
EA200501710A1 (ru) Замещённые карбоновые кислоты
MX2021015874A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EP2124990A4 (en) TUMOR TREATMENT BASED ON ROMIDEPSIN
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.